Literature DB >> 26672027

Pharmacology of Heparin and Related Drugs.

Barbara Mulloy1, John Hogwood2, Elaine Gray2, Rebecca Lever2, Clive P Page2.   

Abstract

Heparin has been recognized as a valuable anticoagulant and antithrombotic for several decades and is still widely used in clinical practice for a variety of indications. The anticoagulant activity of heparin is mainly attributable to the action of a specific pentasaccharide sequence that acts in concert with antithrombin, a plasma coagulation factor inhibitor. This observation has led to the development of synthetic heparin mimetics for clinical use. However, it is increasingly recognized that heparin has many other pharmacological properties, including but not limited to antiviral, anti-inflammatory, and antimetastatic actions. Many of these activities are independent of its anticoagulant activity, although the mechanisms of these other activities are currently less well defined. Nonetheless, heparin is being exploited for clinical uses beyond anticoagulation and developed for a wide range of clinical disorders. This article provides a "state of the art" review of our current understanding of the pharmacology of heparin and related drugs and an overview of the status of development of such drugs.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26672027     DOI: 10.1124/pr.115.011247

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  77 in total

Review 1.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

Review 2.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

Review 3.  Thromboprophylaxis in Head and Neck Microvascular Reconstruction.

Authors:  Manoj Abraham; Arvind Badhey; Shirley Hu; Sameep Kadakia; J K Rasamny; Augustine Moscatello; Yadranko Ducic
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2017-10-31

4.  Surprising absence of heparin in the intestinal mucosa of baby pigs.

Authors:  Yanlei Yu; Yin Chen; Paiyz Mikael; Fuming Zhang; Apryll M Stalcup; Rebecca German; Francois Gould; Jocelyn Ohlemacher; Hong Zhang; Robert J Linhardt
Journal:  Glycobiology       Date:  2016-10-15       Impact factor: 4.313

Review 5.  Recent advances in biotechnology for heparin and heparan sulfate analysis.

Authors:  Meng Qiao; Lei Lin; Ke Xia; Jun Li; Xing Zhang; Robert J Linhardt
Journal:  Talanta       Date:  2020-06-14       Impact factor: 6.057

Review 6.  Advances in the preparation and synthesis of heparin and related products.

Authors:  Sultan N Baytas; Robert J Linhardt
Journal:  Drug Discov Today       Date:  2020-09-16       Impact factor: 7.851

7.  Characterization and Quantification of Highly Sulfated Glycosaminoglycan Isomers by Gated-Trapped Ion Mobility Spectrometry Negative Electron Transfer Dissociation MS/MS.

Authors:  Juan Wei; Jiandong Wu; Yang Tang; Mark E Ridgeway; Melvin A Park; Catherine E Costello; Joseph Zaia; Cheng Lin
Journal:  Anal Chem       Date:  2019-01-31       Impact factor: 6.986

Review 8.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 9.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 10.  Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Maria Gabriella Matera; Clive Page; Paola Rogliani; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.